Publication related to RSI or an RSI staff member
Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population.
Authors
- Yang, Tubao, Yang T, School of Public Health, Central South University, Changsha, Hunan, China.
- Walker, Mark C, Walker MC,
- Krewski, Daniel, Krewski D,
- Yang, Qiuying, Yang Q,
- Nimrod, Carl, Nimrod C,
- Garner, Peter, Garner P,
- Fraser, William, Fraser W,
- Olatunbosun, Olufemi, Olatunbosun O,
- Wen, Shi Wu, Wen SW,
YEAR OF PUBLICATION: 2008
SOURCE: Pharmacoepidemiol Drug Saf. 2008 Mar;17(3):270-7. doi: 10.1002/pds.1538.
JOURNAL TITLE ABBREVIATION: Pharmacoepidemiol Drug Saf
JOURNAL TITLE: Pharmacoepidemiology and drug safety
ISSN: 1099-1557 (Electronic) 1053-8569 (Linking)
VOLUME: 17
ISSUE: 3
PAGES: 270-7
PLACE OF PUBLICATION: England
ABSTRACT:
PURPOSE: To estimate the frequency of exposure to prescription Food and Drug Administration (FDA) category C, D, and X drugs in pregnant women, and to analyze the maternal characteristics associated with such an exposure. METHODS: A 50% random sample of women who gave a birth in Saskatchewan between January 1, 1997 and December 31, 2000 was chosen for the study. The rate of exposure to FDA category C, D, or X drugs recorded in the pharmacist database was estimated. Associations of exposure to FDA category C, D, and X drugs with maternal characteristics were evaluated using multiple logistical regression, with adjusted odds ratios (ORs) and its 95% confidence intervals (CIs) as the association measures. RESULTS: A total of 18 575 women were included in this study. Among them, 3604 (19.4%) had exposure to one or more FDA category C, D, and X drugs during pregnancy. Category C drugs were the most frequently used drugs (15.8%), followed by D drugs (5.2%), and X drugs (3.9%). Women with chronic health conditions had fourfold at increased risk of exposure than women without. Regardless of health status, women who were <20 years of age, who had a parity > or =3, and who were on social assistance plan were at increased risk of pregnancy exposure to these drugs. CONCLUSIONS: About 19.4% pregnant women are exposed to FDA C, D or X drugs during pregnancy. Women with chronic diseases, younger age, increased parity, and under social assistance are at increased risk of exposure to FDA C, D, or X drugs.
PURPOSE: To estimate the frequency of exposure to prescription Food and Drug Administration (FDA) category C, D, and X drugs in pregnant women, and to analyze the maternal characteristics associated with such an exposure. METHODS: A 50% random sample of women who gave a birth in Saskatchewan between January 1, 1997 and December 31, 2000 was chosen for the study. The rate of exposure to FDA category C, D, or X drugs recorded in the pharmacist database was estimated. Associations of exposure to FDA category C, D, and X drugs with maternal characteristics were evaluated using multiple logistical regression, with adjusted odds ratios (ORs) and its 95% confidence intervals (CIs) as the association measures. RESULTS: A total of 18 575 women were included in this study. Among them, 3604 (19.4%) had exposure to one or more FDA category C, D, and X drugs during pregnancy. Category C drugs were the most frequently used drugs (15.8%), followed by D drugs (5.2%), and X drugs (3.9%). Women with chronic health conditions had fourfold at increased risk of exposure than women without. Regardless of health status, women who were <20 years of age, who had a parity > or =3, and who were on social assistance plan were at increased risk of pregnancy exposure to these drugs. CONCLUSIONS: About 19.4% pregnant women are exposed to FDA C, D or X drugs during pregnancy. Women with chronic diseases, younger age, increased parity, and under social assistance are at increased risk of exposure to FDA C, D, or X drugs.
COPYRIGHT INFORMATION: Copyright 2008 John Wiley & Sons, Ltd.
LANGUAGE: eng
DATE OF PUBLICATION: 2008 Mar
DATE COMPLETED: 20080410
DATE REVISED: 20220317
MESH DATE: 2008/04/11 09:00
EDAT: 2008/01/09 09:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: 10.1002/pds.1538 [doi]
OWNER: NLM
Related RSI Experts
Chief Risk Scientist
Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...